XML 22 R15.htm IDEA: XBRL DOCUMENT v3.21.4

RESEARCH AND DEVELOPMENT

12 Months Ended

Sep. 30, 2021

Research And Development [Abstract]

RESEARCH AND DEVELOPMENT [Text Block]

10. RESEARCH AND DEVELOPMENT

Research and development expense recognized in the consolidated statements of comprehensive loss is comprised of the following:

	Year ended	Year ended	Period ended
	September 30, 2021	September 30, 2020	September 30, 2019
	$	$	$
Laboratory costs (see Note 11)	82,871	25,874	27,164
Novel drug development	3,638,910	110,029	-
Patents and related payments	513,302	13,895	-
Salary and subcontractors	1,369,769	43,754	14,845
Share-based compensation (see Note 6)	709,136	161,300	-
	6,313,988	354,852	42,009

X

- References

No definition available.

+ Details

Name:	drug_ResearchAndDevelopmentAbstract
Namespace Prefix:	drug_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of research and development expense. [Refer: Research and development expense]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration